Novartis AG(DE:NOT)
€144.82-0.60 (-0.41%)
DE:NOT
Novartis AG stock forecast
€144.82
At close:-0.60 (-0.41%)
Novartis AG (NOT) Stock Forecast & Price Target
23 Followers
NOT Analyst Ratings
Hold
4Buy8Hold2Sell
Based on 14 analysts giving stock ratings to Novartis AG in the past 3 months
NOT Stock 12 Month Forecast
Average Price Target
€138.53▼(-4.34% Downside)Based on 14 Wall Street analysts offering 12 month price targets for Novartis AG in the last 3 months. The average price target is EUR 138.53 with a high forecast of EUR 162.70 and a low forecast of EUR 113.89. The average price target represents a -4.34% change from the last price of EUR 144.82.
Past 12 Months12 Month ForecastJan2026Oct2026
High€162.70
Average€138.53
Low€113.89
Highest Price TargetHighest€162.70Average Price Target€138.53Lowest Price TargetLowest€113.89
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Kerry Holford | Berenberg Bank | €113.89 | hold | -21.36%Downside | Reiterated | 11/11/26 | ||
| Emmanuel Papadakis | Deutsche Bank | €124.74 | sell | -13.87%Downside | Reiterated | 11/10/26 | ||
| Michael Leuchten | Jefferies | €119.31→€135.58 | hold | -6.38%Downside | Reiterated | 11/09/26 | ||
| James Gordon CFA | Barclays | €135.58 | hold | -6.38%Downside | Reiterated | 11/09/26 | ||
| Graham Parry | Citi | €146.43→€162.70 | buy | 12.35%Upside | Reiterated | 11/06/26 | ||
| Justin Smith | Bernstein | €144.09→€137.84 | hold | -4.82%Downside | Reiterated | 10/29/26 | ||
| Richard Vosser | J.P. Morgan | €146.43→€157.28 | buy | 8.60%Upside | Reiterated | 10/29/26 | ||
| Matthew Weston | UBS | €125.82→€141.01 | hold | -2.63%Downside | Reiterated | 10/28/26 | ||
| James Quigley | Goldman Sachs | €122.57 | sell | -15.37%Downside | Reiterated | 10/28/26 | ||
| Thibault Boutherin | Morgan Stanley | €141.01→€146.43 | buy | 1.11%Upside | Reiterated | 10/28/26 | ||
| Sachin Jain | Bank of America Securities | €162.70 | buy | 12.35%Upside | Reiterated | 10/27/26 | ||
| Trung Huynh | RBC Capital | €130.16→€141.01 | hold | -2.63%Downside | Reiterated | 10/27/26 | ||
| Rajesh Kumar | HSBC | €119.31 | hold | -17.61%Downside | Upgraded | 09/09/26 | ||
 Unknown AnalystNot Ranked | Bank Vontobel | €141.01→€138.84 | hold | -4.13%Downside | Reiterated | 09/07/26 | ||
| Shelby Tucker | TD Cowen | €149.68 | hold | 3.36%Upside | Reiterated | 07/27/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Kerry HolfordBerenberg Bank | HoldReiterated€113.89 | 11/11/26 | -21.36%Downside | ||
| Emmanuel PapadakisDeutsche Bank | SellReiterated€124.74 | 11/10/26 | -13.87%Downside | ||
| Michael LeuchtenJefferies | HoldReiterated€119.31→€135.58 | 11/09/26 | -6.38%Downside | ||
| James Gordon CFABarclays | HoldReiterated€135.58 | 11/09/26 | -6.38%Downside | ||
| Graham ParryCiti | BuyReiterated€146.43→€162.70 | 11/06/26 | 12.35%Upside | ||
| Justin SmithBernstein | HoldReiterated€144.09→€137.84 | 10/29/26 | -4.82%Downside | ||
| Richard VosserJ.P. Morgan | BuyReiterated€146.43→€157.28 | 10/29/26 | 8.60%Upside | ||
| Matthew WestonUBS | HoldReiterated€125.82→€141.01 | 10/28/26 | -2.63%Downside | ||
| James QuigleyGoldman Sachs | SellReiterated€122.57 | 10/28/26 | -15.37%Downside | ||
| Thibault BoutherinMorgan Stanley | BuyReiterated€141.01→€146.43 | 10/28/26 | 1.11%Upside | ||
| Sachin JainBank of America Securities | BuyReiterated€162.70 | 10/27/26 | 12.35%Upside | ||
| Trung HuynhRBC Capital | HoldReiterated€130.16→€141.01 | 10/27/26 | -2.63%Downside | ||
| Rajesh KumarHSBC | HoldUpgraded€119.31 | 09/09/26 | -17.61%Downside | ||
| Unknown AnalystBank VontobelNot Ranked | HoldReiterated€141.01→€138.84 | 09/07/26 | -4.13%Downside | ||
| Shelby TuckerTD Cowen | HoldReiterated€149.68 | 07/27/26 | 3.36%Upside |
Stocks with the Highest Top Analyst Consensus in the General Sector
Best Analysts Covering Novartis AG
3 Months
Success Rate23/31 ratings generated profit
74%
Average Return
+4.10%
Copying David Evans's trades and holding each position for 3 Months would result in 74.19% of your transactions generating a profit, with an average return of +4.10% per trade.
1 Year
Success Rate31/31 ratings generated profit
100%
Average Return
+16.39%
Copying David Evans's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +16.39% per trade.
2 Years
Success Rate31/31 ratings generated profit
100%
Average Return
+32.07%
Copying David Evans's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +32.07% per trade.
NOT Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 20 | 18 | 19 | 19 | 16 |
| Hold | 14 | 13 | 23 | 29 | 32 |
| Sell | 2 | 2 | 3 | 4 | 5 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 36 | 33 | 45 | 52 | 53 |
In the current month, NOT has received 16 Buy Ratings, 32 Hold Ratings, and 5 Sell Ratings. NOT average Analyst price target in the past 3 months is 138.53.
NOT Financial Forecast
High€2.10
Consensus€2.01
Low€1.89
NOT Earnings Forecast
Next quarter’s earnings estimate for NOT is EUR 2.01 with a range of EUR 1.89 to EUR 2.10. The previous quarter’s EPS was EUR 2.19. Its overall industry beat the EPS estimate 50.49% of the time in the past 12 months.
High€13.6B
Consensus€13.1B
Low€12.5B
NOT Sales Forecast
Next quarter’s sales forecast for NOT is EUR 13.08B with a range of EUR 12.50B to EUR 13.59B. The previous quarter’s sales results were EUR 12.88B. Its overall industry beat sales estimates 63.25% of the time in the past 12 months.
NOT Stock Forecast FAQ
What is DE:NOT’s average 12-month price target, according to analysts?
Based on analyst ratings, Novartis AG’s 12-month average price target is €138.53.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Novartis AG a Buy, Sell or Hold?
Novartis AG has a consensus rating of Hold, which is based on 4 buy ratings, 8 hold ratings and 2 sell ratings.
What is Novartis AG’s share price target?
The average share price target for Novartis AG is €138.53. This is based on 14 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €162.70, and the lowest forecast is €113.89. The average share price target represents a 4.34% decrease from the current price of €144.82.
What do analysts say about Novartis AG?
Novartis AG’s analyst rating consensus is a Hold. This is based on the ratings of 14 Wall Street analysts.
How can I buy shares of Novartis AG?
To buy shares of DE:NOT, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
